Drug Profile
Eltrapuldencel-T - Lisata Therapeutics
Alternative Names: Autologous stem cell therapy - California Stem Cell; Cancer stem cell - California Stem Cell; CLBS 20; DC-TC; DC/DT; MAC-VAC; Malignant melanoma stem cell therapy - NeoStem Oncology; Melapuldencel-T; NBS 20Latest Information Update: 19 Sep 2022
Price :
$50
*
At a glance
- Originator Hoag Memorial Hospital Presbyterian
- Developer Lisata Therapeutics
- Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Stem cell therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Colorectal cancer; Liver cancer; Lung cancer; Ovarian cancer
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics
- 23 Apr 2020 Immunogenicity data from a phase II trial in Melanoma released by AIVITA Biosciences
- 25 Apr 2016 Caladrius Biosciences terminates a phase III trial for Malignant melanoma (late-stage disease) in USA (NCT01875653)